Si-Bone Stock Price, News & Analysis

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced that it will release its third quarter 2024 financial results after the market closes on Tuesday, November 12, 2024. Following the release, the company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results.

Investors interested in participating in the conference call can register using the provided link. Additionally, a live audio webcast will be available on the 'Investors' section of SI-BONE's website. The webcast will be archived and accessible for replay for at least 90 days after the event.

SI-BONE, a medical device company focused on sacropelvic disorders, announced the first-in-patient procedures with their FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). This innovative system, which received 510(k) clearance in August 2024, addresses the challenges of pelvic fragility fractures in patients with poor bone quality. The TNT implant features a pelvis-specific design for improved fixation and reduced screw backout risk, and it is the first 3D-printed transiliac-transsacral screw cleared for market use in the U.S. Surgeons praised its streamlined instrumentation and efficient implantation process, which minimizes operating time and enhances patient recovery. SI-BONE’s CEO, Laura Francis, highlighted the system's potential to meet the unmet clinical needs of complex pelvic fractures and expand their leadership in the sacropelvic space.

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will host a fireside chat on September 4, 2024, at 10:45 a.m. Eastern Time.

Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's operations and future prospects in the medical device industry.

SI-BONE, Inc. (Nasdaq: SIBN) has received FDA 510(k) clearance and Breakthrough Device Designation for its iFuse TORQ TNT™ Implant System (TNT). This next-generation technology is designed for pelvic fragility fracture fixation and sacroiliac joint fusion. The TNT system features a porous threaded implant capable of spanning the posterior pelvis, addressing the specific needs of the sacrum and ilium.

The FDA recognized TNT's potential to provide more effective treatment than the current standard of care, cannulated screws. TNT aims to improve early fixation and reduce screw backout, potentially allowing for earlier patient weight-bearing and mobilization. This innovation is particularly significant for the growing elderly population affected by pelvic fragility fractures.

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management will host a fireside chat on August 14, 2024, at 3:30 p.m. Eastern Time.

Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's growth strategies and market position in the medical device industry.

SI-BONE, Inc. (Nasdaq:SIBN) reported strong Q2 2024 financial results, with worldwide revenue reaching $40.0 million, a 20% increase year-over-year. U.S. revenue grew 21% to $37.8 million. The company improved its net loss by 20% to $8.9 million and reduced its Adjusted EBITDA loss by 43% to $2.7 million. SI-BONE ended the quarter with $151.5 million in cash and equivalents.

Operational highlights include a 23% increase in U.S. active physicians to over 1,150. The company also reported positive 5-year results from the SALLY clinical trial and early interim results from the STACI study. SI-BONE has increased its 2024 revenue guidance to $165-$167 million and expects to achieve positive Adjusted EBITDA in Q4 2024.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company focused on musculoskeletal disorders of the sacropelvic anatomy, has announced it will release its second quarter 2024 financial results on August 5, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can register for the call using the provided link. A live audio webcast will be available on the company's website, and a replay will be accessible for at least 90 days after the event.

SI-BONE, a company specializing in solutions for musculoskeletal disorders, will present at the Truist Securities 2024 MedTech Conference in Boston on June 18, 2024. Management will hold a fireside chat at 3:40 p.m. ET / 12:40 p.m. PT. Investors can listen to the live webcast by registering through a provided link. The webcast will also be available on the company's website and archived for 90 days post-event.

SI-BONE, Inc. expands its product line with the launch of the Granite 9.5 implant, designed for sacroiliac fusion and spinopelvic fixation. The smaller diameter implant received FDA clearance in January 2024. Surgeons praise the implant for its ease of use and potential for improved patient outcomes. The company aims to target a large market with the new offering.